Spots Global Cancer Trial Database for Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Official Title: Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Study ID: NCT05701436
Conditions
Study Description
Brief Summary: This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Detailed Description: Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Contact Details
Name: Mingxin Pan, Prof
Affiliation: Study Principal Investigator Southern Medical University, China
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
